Chronic inflammatory demyelinating polyneuropathy (CIDP)- Pipeline Insight, 2025

DelveInsight’s, “Chronic inflammatory demyelinating polyneuropathy (CIDP)- Pipeline Insight, 2025” report provides comprehensive insights about 2+ companies and 4+ pipeline drugs in Chronic inflammatory demyelinating polyneuropathy (CIDP)pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Chronic inflammatory demyelinating polyneuropathy (CIDP): Understanding

Chronic inflammatory demyelinating polyneuropathy (CIDP): Overview

Chronic inflammatory demyelinating polyneuropathy (CIDP; also known as chronic inflammatory demyelinating polyradiculoneuropathy) is an autoimmune-mediated inflammatory disease affecting the peripheral nerves and the nerve roots. This disorder is characterized by damage to the myelin sheath of the peripheral nerves and by immune infiltrates. The disorder causes progressive motor and sensory deficits that manifest as proximal and distal muscle weakness, numbness, paraesthesia, sensory ataxia, and often severe disability, which hallmark severe demyelination and secondary axonal loss of peripheral nerves. CIDP has a slow onset with continued progression over more than two months and typically evolves as a relapsing, progressive or monophasic disorder.

Common symptoms of CIDP include tingling, gradual weakness, loss of reflexes, balance issues, difficulty walking, and reduced sensation in the arms and legs, often starting with an inability to feel a pinprick. These symptoms typically develop over weeks to months and can progressively worsen, affecting a person's ability to perform everyday tasks. As the condition advances, muscle weakness may become more pronounced, leading to difficulty with mobility and coordination.

CIDP is an acquired disorder that targets the peripheral nervous system, leading to the destruction of the myelin sheath surrounding nerves. Myelin, produced by Schwann cells, facilitates rapid nerve signal transmission. In CIDP, inflammation infiltrates the affected nerves, causing demyelination and impairing nerve function. Over time, Schwann cells proliferate, and collagen is deposited, resulting in nerve thickening and the characteristic ""onion bulb"" appearance. This damage disrupts nerve communication, leading to muscle weakness and other neurological symptoms.

Diagnosing CIDP can be challenging due to its similarity to Guillain-Barré Syndrome (GBS). If symptoms persist for more than 8 weeks, CIDP may be suspected. A thorough evaluation by a neurologist or neuromuscular specialist is essential, including a detailed medical history and physical exam to assess strength, sensation, and reflexes. Tests such as electromyography (EMG), nerve conduction studies, lumbar puncture, and occasionally a nerve biopsy may be performed to confirm the diagnosis and rule out other conditions. First-line treatments for CIDP include corticosteroids, plasmapheresis (PE), and intravenous immunoglobulin (IVIg), which aim to suppress or modulate the immune system, providing symptom relief for 60-80% of patients. Corticosteroids like prednisone and dexamethasone are used initially in high doses and tapered to maintain remission, though long-term use can cause side effects. PE removes harmful antibodies from the blood and is often used for refractory cases or when other treatments are not viable. IVIg, a mixture of antibodies from healthy donors, has shown effectiveness in improving symptoms and maintaining remission in CIDP patients. Subcutaneous immunoglobulin (SCIg) is a newer alternative for long-term maintenance, offering good efficacy and quality of life benefits for some patients.

""Chronic inflammatory demyelinating polyneuropathy (CIDP)- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline landscape is provided which includes the disease overview and Chronic inflammatory demyelinating polyneuropathy (CIDP) treatment guidelines. The assessment part of the report embraces, in depth Chronic inflammatory demyelinating polyneuropathy (CIDP) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic inflammatory demyelinating polyneuropathy (CIDP)collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic inflammatory demyelinating polyneuropathy (CIDP) R&D. The therapies under development are focused on novel approaches to treat/improve Chronic inflammatory demyelinating polyneuropathy (CIDP).

Chronic inflammatory demyelinating polyneuropathy (CIDP) Emerging Drugs Chapters

This segment of the Chronic inflammatory demyelinating polyneuropathy (CIDP)report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic inflammatory demyelinating polyneuropathy (CIDP) Emerging Drugs

Riliprubart: Sanofi

Riliprubart (SAR445088) is a potential first-in-class, IgG4 humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway of the innate immune system. By blocking C1s, riliprubart has the potential to inhibit key inflammatory mechanisms that drive demyelination and axonal damage in chronic inflammatory demyelinating polyneuropathy (CIDP). Riliprubart has convenient subcutaneous route of administration. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Chronic inflammatory demyelinating polyneuropathy (CIDP).

Batoclimab: Immunovant Sciences GmbH

Batoclimab is a human monoclonal antibody directed against the Neonatal Crystallizable Fragment Receptor (FcRn), with potential immunomodulating activity. Upon administration, batoclimab targets and binds to FcRn at the Immunoglobulin G (IgG) binding site, thereby preventing the interaction between FcRn and the serum protein IgG. By preventing FcRn/IgG binding, batoclimab blocks the FcRn-mediated rescue of IgG, enables IgG degradation and prevents IgG-mediated inflammation. IgG plays a key role in many autoimmune diseases and is an important factor in inflammatory processes. Currently, the drug is in Phase II stage of its development for the treatment of Chronic inflammatory demyelinating polyneuropathy (CIDP).

Further product details are provided in the report……..

Chronic inflammatory demyelinating polyneuropathy (CIDP): Therapeutic Assessment

This segment of the report provides insights about the different Chronic inflammatory demyelinating polyneuropathy (CIDP) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic inflammatory demyelinating polyneuropathy (CIDP)

There are approx. 2+ key companies which are developing the therapies for Chronic inflammatory demyelinating polyneuropathy (CIDP). The companies which have their Chronic inflammatory demyelinating polyneuropathy (CIDP) drug candidates in the most advanced stage, i.e. Phase III include, Sanofi

Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic inflammatory demyelinating polyneuropathy (CIDP): Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Chronic inflammatory demyelinating polyneuropathy (CIDP) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic inflammatory demyelinating polyneuropathy (CIDP) drugs.

Chronic inflammatory demyelinating polyneuropathy (CIDP) Report Insights

Chronic inflammatory demyelinating polyneuropathy (CIDP)Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Chronic inflammatory demyelinating polyneuropathy (CIDP) Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Chronic inflammatory demyelinating polyneuropathy (CIDP) drugs?

How many Chronic inflammatory demyelinating polyneuropathy (CIDP) drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic inflammatory demyelinating polyneuropathy (CIDP)?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic inflammatory demyelinating polyneuropathy (CIDP) therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Chronic inflammatory demyelinating polyneuropathy (CIDP) and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Sanofi

Immunovant Sciences GmbH

Key Products

Riliprubart

Batoclimab


Please Note: It will take 1-2 business days to complete the report upon order confirmation.